卡普赛珠单抗隔日给药治疗免疫介导性血栓性血小板减少性紫癜
该回顾性队列纳入2018至2021年奥地利和德国七家医疗中心的25例免疫介导性血栓性血小板减少性紫癜患者,分析卡普赛珠单抗隔日给药的风险与获益。隔日给药看似可行,多数患者维持正常血小板计数,5例发生加重或复发后恢复每日给药;16例重复检测血管性血友病因子活性显示24和48小时后抑制充分。作者认为每日治疗3至4周后,特定患者可安全考虑延长给药间隔至隔日。
要点
- 25例iTTP患者中,卡普赛珠单抗隔日给药看似可行,多数维持正常血小板计数。
- 5例发生iTTP加重或复发,导致恢复每日卡普赛珠单抗给药。
- 16例重复检测VWF活性,显示24和48小时后抑制充分,与已发表药效学一致。
核心结论
- 每日治疗3至4周后,特定患者可安全考虑将卡普赛珠单抗给药间隔从每日延长至隔日。
- 低危患者可讨论更早调整给药间隔,但需密切监测血栓性微血管病的临床和实验室特征。
研究设计与样本
- 回顾性队列研究,纳入2018至2021年奥地利和德国七家医疗中心的25例接受卡普赛珠单抗治疗的iTTP患者。
主要发现
- 隔日给予卡普赛珠单抗看似可行,多数患者维持正常血小板计数。
- 5例患者发生iTTP加重或复发,导致恢复每日卡普赛珠单抗给药。
- 25例中16例重复测量VWF活性,记录到卡普赛珠单抗在24和48小时后抑制充分,与已发表药效学一致。
临床怎么用
- 作者认为每日治疗3至4周后,特定患者可安全考虑隔日给药。
- 作者认为低危患者可讨论更早调整给药间隔,但需密切监测血栓性微血管病的临床和实验室特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The anti-von Willebrand factor (VWF) nanobody caplacizumab directly prevents the fatal microthrombi formation in immune-mediated thrombotic thrombocytopenic purpura (iTTP), thereby adding a new therapeutic principle to the treatment of this disorder. However, real-world treatment modalities beyond clinical trials remain heterogeneous. METHODS: Here, we describe the risks and benefits of an alternate-day dosing regimen for caplacizumab by thoroughly analyzing the timing and outcome of this approach in a retrospective cohort of 25 iTTP patients treated with caplacizumab at seven different medical centers in Austria and Germany between 2018 and 2021. RESULTS: Alternate-day dosing of caplacizumab appeared feasible and led to persisting normal platelet counts in most patients. Five patients experienced iTTP exacerbations or relapses that led to the resumption of daily caplacizumab application. VWF activity was repeatedly measured in 16 of 25 patients and documented sufficient suppression by caplacizumab after 24 and 48 h in line with published pharmacodynamics. CONCLUSION: Extension of caplacizumab application intervals from daily to alternate-day dosing may be safely considered in selected patients after 3 to 4 weeks of daily treatment. Earlier modifications may be discussed in low-risk patients but require close monitoring for clinical and laboratory features of thrombotic microangiopathy.
引用
- Kühne L, Kaufeld J, Völker LA, et al. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura. J Thromb Haemost. 2022. PMID: 35000278. doi:10.1111/jth.15637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。